PROTAC Targeted Protein Degraders Market Clinical Trials Insight to 2027 - Emerging PROTAC Therapeutics Set to Revolutionize Targeted Protein Degradation in Clinical Trials [Yahoo! Finance...
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Opportunity & Clinical Trials Insight 2027" report has been added to ResearchAndMarkets.com's offering. First conceptualized in the early 2000s, proteolysis-targeting chimeras (PROTACs) are emerging as a transformative approach in targeted therapies. By harnessing the body's natural ubiquitin-proteasome system, PROTACs selectively eliminate specific proteins implicated in various diseases, particularly those that have been historically deemed undruggable. This innovative therapeutic modality is gaining traction in both academic and industrial settings, with a focus on addressing significant gaps in treatment options for patients with complex diseases. Global PROTAC Targeted Protein Degraders Market Opportunity & Clinical Trials Insight 2027 Report Finding & Inclusions: First PROTAC Drug Approval Expected By 2027 Global & Regional PROTAC Drug Market Trends Insight First 12 Months & First 5 Years Market Size Estimates Since Approval Global PROTAC Drugs Clinical Trials Insigh
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas, Inc. (NASDAQ: ARVN) had its price target raised by analysts at Oppenheimer Holdings Inc. from $40.00 to $45.00. They now have an "outperform" rating on the stock.MarketBeat
- Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $82.00 price target on the stock, down previously from $88.00.MarketBeat
- Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $57.00 price target on the stock.MarketBeat
- Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Stifel Nicolaus from $63.00 to $51.00. They now have a "buy" rating on the stock.MarketBeat
- Arvinas, Inc. (NASDAQ: ARVN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.MarketBeat
ARVN
Earnings
- 2/11/25 - Beat
ARVN
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/11/25 - Form S-8
- 2/11/25 - Form 10-K
- ARVN's page on the SEC website